11-14-2005 08:31 AM CET - Health & Medicine

Contract Research Organization for the Improvement of Cardiovascular safety is established in Erfurt, Germany

Press release from: CardioSec Clinical Research GmbH

The newly established CardioSec Clinical Research GmbH in Erfurt, Germany
(www.cardiosec.com) carries out clinical trials under contract from the international pharmaceutical industry to improve the cardio-vascular safety of drugs, that is, the QT studies.

More than 85% of all known major side effects of drugs affect the heart. International heath authorities and the pharmaceutical industry are increasingly demanding that clinical studies for the identification of such risks be carried out.

CardioSec is establishing a clinical unit with the necessary high level of technical equipment to carry out such studies. It has medical and technical personnel with extensive experience in clinical trials.

Doerte Wolf, MD, as managing partner, is taking over the medical direction of the company. Associate Professor Wilhelm Haverkamp (Charite, Berlin), an internationally acknowledged expert in the area of cardiology is supporting the company as scientific advisor.

Cardiosec is commencing business at the beginning of 2006 in modern equipped rooms in Erfurt.


CardioSec is a contract research organisation (CRO) in the area of drug development. The company offers design, implementation of and evaluation of clinical trials, especially those in the area of cardiology.

CardioSec Clinical Research GmbH
Dr. Hans-Joachim Janhsen
Nerlystr. 1
D-99094 Erfurt
phone: +49-(0)361 216 72 76
fax: +49-(0)361 216 72 75
mail: hans-joachim.janhsen@cardiosec.com
web: www.cardiosec.com

This release was published on openPR.
News-ID: 481 • Views: 1229
More releasesMore releases

You can edit or delete your press release here: